Reagent | sPLA2-IIA

Key benefits of the Randox sPLA2-IIA assay

clock-11

Latex Enhanced Immunoturbidimetric method
Randox utilise the automated L.E.I method offering a more convenient and high performance method for sPLA2-IIA measurement compare to traditional ELISA testing.

icons ++3

Exceptional correlation with the standard method
correlation coefficient of r=0.95 was displayed when the Randox methodology was compared against commercially available methods.

icons ++

Liquid ready-to-use assay
The Randox sPLA2-IIA assay is available in a liquid ready-to-use format for convenience and ease-of-use.

control bottle v1-01

Dedicated sPLA2-IIA controls and calibrator available
Randox offer dedicated sPLA2-IIA calibrator and controls, offering a complete testing package.

icons ++4

Applications are available
Applications are available detailing instrument-specific settings for the convenient use of the Randox sPLA2-IIA assay on a wide range of clinical chemistry analysers. Contact us to enquire about your specific analyser.

Cat NoSize   
PLA8380R1 1 x 12.7ml
R2 1 x 12.7ml
EnquireKit Insert RequestMSDS

Instrument Specific Applications (ISA’s) are available for a wide range of biochemistry analysers.  Contact us to enquire about your specific analyser.

  • Biological Significance
  • Clinical significance
  • Clinical Utility in CVD

The secretory phospholipase A2 family comprises a large range of enzymes, their main function is to hydrolyse phospholipids from the cell membrane surface and lipoproteins. sPLA2-IIA is a prototypic member of the group II sPLA2 subfamily and has been shown to be induced by pro-inflammatory stimuli in a wide variety of cells and tissues. It has been found to be associated with a number of inflammatory diseases including, coronary artery disease, and atherosclerosis. These factors have contributed to its nickname, “inflammatory sPLA21, 2.

Fig. 1 highlights the role of sPLA2-IIA in hydrolysing phospholipid from cell membrane surfaces, platelet-activating factor (PAF) and oxidativelymodified lipoproteins. Once hydrolysed, multiple bioactive lipids are produced including arachidonic acid which in turn is hydrolysed by cyclooxygenase to generate prostaglandins, lipoxygenase to produce lipoxines leukotriens and cytochromome P450 to generate epoxides fatty acid alcohols. In contrast, Lp-PLA2 requires oxidised phospholipids (ox-phosphatidyl-choline) as a substrate 3.

sPLA2-llA is already expressed in the normal arterial wall and its expression is readily up-regulated by inflammatory stimuli. Its role in producing fatty acids and biologically active phospholipids is linked to platelet, monocyte, and endothelial activation, processes known to be critical steps in atherogenesis 4. Research indicates that serum sPLA2-IIA levels are higher among CAD patients than normal subjects. The lipid mediators produced through sPLA2-IIA and their related lipids in the arterial wall can stimulate T cells and macrophages to synthesize and release the pro-atherogenic and pro-inflammatory cytokines, which in turn induce sPLA2-IIA production in the atherosclerotic walls 5.

1. European Heart Journal (2019): Group IIA secretory phospholipase A2, inflammation, and incident cardiovascular disease: An analysis from the JUPITER Trial 6

Objective: A study prospectively evaluated 17,802 patients enrolled in the JUPITER Trial to determine the association of sPLA2-IIA mass with incident CVD in a primary prevention population with chronic inflammation.

Conclusion: sPLA2-IIA plays an integral pro-inflammatory role in regulating vascular inflammation. The JUPITER trial found that elevated levels of sPLA2-IIA at baseline was significantly associated with a greater risk of incident CVD.

2. Journal of the American College of Cardiology (2013): Secretory phospholipase A2-IIA and cardiovascular disease: A Mendelian randomization study 7

Objective: A Mendelian randomisation meta-analysis prospectively examined 19 general population studies incorporating 8,021 incident, 7,513 prevalent major vascular events (MVE) in 74,684 patients and 10 acute coronary syndrome (ACS) cohorts incorporating 2,520 recurrent MVE in 18,355 patients to determine the role of sPLA2-IIA in cardiovascular disease (CVD).

Conclusion: sPLA2-IIA is thought to be the most highly expressed of the enzymes and observational studies have indicated that higher circulating sPLA2-IIA mass is associated with an increased risk of CVD and MVE.

sPLA2-IIA Control

sPLA2-IIA Calibrator

Reagents Home

Resource Hub

Request a meeting
×
Make an Enquiry - RX series
×
Make an Enquiry - Reagents
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
×
Make an Enquiry - Quality Control
×
Make an Enquiry - RIQAS
×
Make an Enquiry - RIQAS
×
Make an Enquiry - Quality Control
×
Make an Enquiry
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Biochip
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Molecular
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Future Diagnostics
×
Make an Enquiry - RX series (Product)
×
Make an Enquiry - Quality Control
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - RIQAS
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Por favor, introduzca sus datos para ver nuestro último seminario
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje Polityki Prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
×
Wyślij zapytanie
    Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności .
×
귀하의 문의 사항 제출
    Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
귀하의 문의 사항 제출
×
귀하의 문의 사항 제출
×
귀하의 문의 사항 제출
×
Downloads
×
Contact

<p>

    Randox Clinical Chemistry Products Join the Randox Laboratories Mailing List * I would like to receive emails with new product releases and updates from Randox Laboratories, market trends, and more. I do not want to receive email marketing from Randox. Signing up to our mailing list is quick and easy. We do not want to send you any spam or junk emails, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promises never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
</p>

×
Enquire Now - Coronavirus Testing
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details safe and secure. Read more in our Privacy Policy.
×